Patent · US Active

Genomic engineering of pluripotent cells

US10287606B2 · kind B2 · utility

22Cited by
28References
24Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 20, 2017
Grant dateMay 14, 2019
Priority date
Expiry dateNov 20, 2037

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.